Cumberland Pharmaceuticals to acquire Theravance Biopharma’s Vibativ
Specialty pharmaceutical company Cumberland Pharmaceuticals has reached an agreement to acquire Vibativ from Theravance Biopharma.
Vibatin (telavancin) is an anti-infective for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of gram-positive bacterial pathogens, including those that are considered difficult to treat and multidrug-resistant.
Cumberland will assume full responsibility for the product, including its marketing, distribution, manufacturing and regulatory activities.
“Vibativ is a lifesaving product for certain difficult to treat infections, and we are honored to be selected to acquire and transition the brand to our existing hospital acute care infrastructure,” Cumberland Pharmaceuticals CEO A.J. Kazimi said. Our immediate plan for Vibativ is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion and medical initiatives to help ensure that the product is available to the patients who need it. We are very optimistic about the opportunity that Vibativ will offer Cumberland.”
Genoa Healthcare debuts 14 pharmacies
Genoa Healthcare, a provider of pharmacy, outpatient telepsychiatry and medication management services, has expanded with the opening of 14 pharmacies.
Genoa has opened in the following locations Laredo, Texas; Grants Pass, Ore.; Hannibal, Ore.; Lufkin, Texas; Weslaco, Texas; Toledo, Ohio; Valley Cottage, N.Y.; Biddeford, Maine; St. Louis Park, Minn.; Hartford, Conn; Eugene, Ore.; New Port Richey, Fla.; Tallahassee, Fla,; and Williamsburg, Va.
These new locations bring the total number of pharmacies opened this year to 51 for a total of 437 pharmacies.
“Genoa Healthcare is grateful to be working with our center partners in these communities to bring quality service to those struggling with behavioral and other complex health conditions,” the company said.
Hikma, Vectura to develop generic versions of GSK’s Ellipta portfolio
Hikma Pharmaceuticals has signed an agreement with Vectura Group for the global development and commercialization of generic versions of GlaxoSmithKlines’s Ellipta portfolio, which will utilize Vectura’s proprietary “open-inhale-close” dry powder inhaler device.
“The generic respiratory market is a key area of pipeline focus for Hikma.This agreement leverages the investment we have made and the experience we have gained through our generic Advair Diskus program,” Hikma CEO Siggi Olafsson said in a statement. “By strengthening and expanding our partnership with Vectura, we will develop a pipeline of complex respiratory products that will enable us to deliver sustainable long-term growth.”
Vectura and Hikma believe the open-inhale-close dry powder inhaler device has the potential to be developed as a drug-device combination for generic versions of the GSK Ellipta portfolio.
Net sales for Ellipta products in the United States are projected to be $4 billion by 2024 and approximately $5.5 billion globally, the company said.
The open-inhale-close dry powder inhaler program includes the development of generics of up to five GSK respiratory medicines.
Hikma and Vectura have agreed to develop and commercialize at least three of the portfolio products. A generic version of Breo Ellipta (fluticasone furoate and vilanterol trifenatate) will be prioritized for the first wave of development. Pharmaceutical and device development work has progressed in parallel with partnering discussions.
The new device, an evolution of Vectura’s lever-operated multidose device, builds on Vectura and Hikma’s shared experience with the generic Advair Diskus program, enabling accelerated development under this new agreement.